Karine Charrière

Dr. Karine Charrière

orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
KCKarine Charrière
Karine Charrière
VSVincent Schneider
Vincent Schneider
MPManon Perrignon-Sommet
Manon Perrignon-Sommet
Gérard Hubert LizardGérard Hubert Lizard
Gérard Hubert Lizard
ABAlexandre Benani
Alexandre Benani
Anne VEJUXAnne VEJUX
Anne VEJUX
Neuroinflammation, a hallmark of various central nervous system disorders, is often associated with oxidative stress and neuronal or oligodendrocyte cell death. It is therefore very interesting to target neuroinflammation pharmacologically. One therapeutic option is the use of nutraceuticals, particularly apigenin. Apigenin is present in plants: vegetables (parsley, celery, onions), fruits (oranges), herbs (chamomile, thyme, oregano, basil), and some beverages (tea, beer, and wine). This review explores the potential of apigenin as an anti-inflammatory agent across diverse neurological conditions (multiple sclerosis, Parkinson’s disease, Alzheimer’s disease), cancer, cardiovascular diseases, cognitive and memory disorders, and toxicity related to trace metals and other chemicals. Drawing upon major studies, we summarize apigenin’s multifaceted effects and underlying mechanisms in neuroinflammation. Our review underscores apigenin’s therapeutic promise and calls for further investigation into its clinical applications.

1 June 2021 in The Journal of Steroid Biochemistry and Molecular Biology
Verified
Journal Article
Closed access
Anne VEJUXAnne VEJUX
Anne VEJUX
IGImen Ghzaiel
Imen Ghzaiel
TNThomas Nury
Thomas Nury
VSVincent Schneider
Vincent Schneider
KCKarine Charrière
Karine Charrière
Gérard Hubert LizardGérard Hubert Lizard
Gérard Hubert Lizard

Verified
Journal Article
Open access
PDF file
KCKarine Charrière
Karine Charrière
IGImen GHZAIEL
Imen GHZAIEL
Gérard Hubert LizardGérard Hubert Lizard
Gérard Hubert Lizard
Anne VEJUXAnne VEJUX
Anne VEJUX
Neurodegenerative diseases represent a major public health issue and require better therapeutic management. The treatments developed mainly target neuronal activity. However, an inflammatory component must be considered, and microglia may constitute an important therapeutic target. Given the difficulty in developing molecules that can cross the blood–brain barrier, the use of food-derived molecules may be an interesting therapeutic avenue. Docosahexaenoic acid (DHA), an omega-3 polyunsaturated fatty acid (22:6 omega-3), has an inhibitory action on cell death and oxidative stress induced in the microglia. It also acts on the inflammatory activity of microglia. These data obtained in vitro or on animal models are corroborated by clinical trials showing a protective effect of DHA. Whereas DHA crosses the blood–brain barrier, nutritional intake lacks specificity at both the tissue and cellular level. Nanomedicine offers new tools which favor the delivery of DHA at the cerebral level, especially in microglial cells. Because of the biological activities of DHA and the associated nanotargeting techniques, DHA represents a therapeutic molecule of interest for the treatment of neurodegenerative diseases.

26 January 2023 in Clinical Chemistry and Laboratory Medicine (CCLM)
Verified
Journal Article
Open access
PDF file
KCKarine Charrière
Karine Charrière
LPLionel Pazart
Lionel Pazart
In May 2022, the European Regulation 2017/746 (IVDR) came into force. It changes the approach of in vitro medical devices (IVD-MDs) for industry and institutions. It reinforces the clinical evidence requirements to improve performance, safety and transparency. Despite extended transition periods and existing guides, IVDR remains difficult to interpret and bringing devices into compliance requires efforts. The generation of clinical evidence is essential to demonstrate compliance with IVDR, and encompasses scientific validity, analytical performance and clinical performance. It is required to demonstrate, per intended use in the target population and clinical care pathway, IVD-MDs clinical performance (compared to a predefined clinical performance). Thus, there is a need for IVD-manufacturers and end-users in health care institutions, to obtain guidance on how to generate this clinical evidence. This article aims industrials and clinicians to identify key steps imposed by the IVDR for bringing IVD-MDs to the EU-market. We propose a general view of performance evaluation requirements for IVD-MDs and provide key references, including how to establish study design that will enable to document clinical performance of existing, refined or emerging medical tests. Finally, we propose a roadmap to address the relevant questions and studies in relation to the documents requested in the IVDR.

1 January 2012
Verified
Conference Paper
Open access
KCKarine Charrière
Karine Charrière
JGJean Sebastien Guerrini-Chappuis
Jean Sebastien Guerrini-Chappuis
BWBruno Wacogne
Bruno Wacogne
ARAlain ROULEAU
Alain ROULEAU
CECeline Elie-Caille
Celine Elie-Caille
WBWilfrid Boireau
Wilfrid Boireau
The SCITEPRESS Digital Library offers online access to all papers presented at INSTICC conferences, as well as a few conferences organized by others.

13 June 2026 in Addiction Science & Clinical Practice
Verified
Journal Article
Open access
PDF file
LDLilou Duquet
Lilou Duquet
ABAnastasia Boitel
Anastasia Boitel
SGSilvio Galli
Silvio Galli
KCKarine Charrière
Karine Charrière
FMFred Mauny
Fred Mauny
JGJulie Giustiniani
Julie Giustiniani
Background: Physical activity has been shown to improve sleep and may serve as an effective adjunctive therapy in the treatment of alcohol use disorder (AUD). However, few studies have examined the impact of Adapted Physical Activity (APA) programs on sleep in individuals with AUD. This pilot randomized controlled trial (RCT), APhysOH, aims to assess the feasibility of an RCT evaluating the effects of an APA intervention on sleep, alcohol use, and mental and physical health outcomes in individuals with AUD. Methods: Forty participants will be recruited and randomized to either an intervention group, referred to as the supervised group ( n = 30), or a control group, referred to as the autonomous group ( n = 10). The intervention consists of a 12-week APA program tailored to the abilities of patients with AUD and designed to improve sleep. It includes aerobic and resistance-based exercises delivered through three one-hour morning sessions per week. The control group will continue usual care and receive educational material on the benefits of physical activity for AUD and sleep. The primary objective of this study is to assess feasibility. Secondary objectives are to evaluate the impact of a supervised APA program on sleep, addiction severity, physical fitness, functional capacity, and mental health in patients with AUD. Both objective and subjective measures will be used, including biomarkers, actigraphy, physical performance tests, validated questionnaires, and diaries recording sleep, physical activity, and alcohol consumption. Discussion: Findings from this pilot RCT protocol will inform the design of future large-scale trials by evaluating the feasibility of this type of intervention. The study will also generate preliminary data to estimate the potential effects of APA on sleep, addiction severity, and physical and mental health in individuals with AUD. Trial registration: ClinicalTrials.gov identifier: NCT06706349. Registered on 2 June 2024; last updated on 26 November 2024. Sponsor: CHU Besançon, France.